HSBC has initiated coverage of SRF with buy rating and target price of Rs 3,390. Analysts said SRF was one of India’s largest chemical manufacturing companies, with 50% of its revenues coming from overseas. Improving fundamentals in specialty chemicals and performance films to drive 26% compound annual growth rate (CAGR) of earnings during FY27-FY29.He sees some risks in the refrigerant gas segment. Analysts also pointed to some key downside risks, including tariff/anti-dumping duties, further decline in prices, raw material shortage due to the West Asia crisis and high inventories in the agro-chemicals segment.Jefferies recommends buy on Grasim with a target price of Rs 3,440. Analysts said Grasim is expected to get Rs 397 crore from UltraTech Cement’s Rs 240/share payout in Q4FY26, a sharp step up from previous years. Over the past two years there have been suggestions that Grasim retained half of the dividend to finance new businesses, particularly paints.With the dividend pool from UltraTech looking structurally elevated, Grasim now has greater capital availability with optionality across growth funding, deleveraging and shareholder returns – and, if executed judiciously, scope to reduce the holdco discount.Nomura recommends buy on Adani Ports & SEZ with a target price of Rs 1,930. Analysts said the company is entering subsea in Europe to boost marine business. And its expansion into Europe has significantly increased the maritime sector’s international presence. He believes that the addition of the Astro Atlas ship will enhance the company’s operational capabilities. By FY31, in the maritime sector, ADSEZ targets around 200 ships, revenue of Rs 6,000 crore and capital expenditure of Rs 13,000 crore, which appears to be largely achievable.CLSA has a Hold rating on Tata Power with a target price of Rs 415, up from earlier target of Rs 369. Analysts said FY26 was a weak year. Mundra IPP and solar EPC disappointed while coal mines shined during Q4FY26. During FY26, Mundra IPP losses and slow solar EPC and RE IPPs led to losses, but they feel the worst has already passed.Goldman Sachs recommends Buy on Newland Labs with a target price of Rs 19,550, higher than the previous target of Rs 17,275. Analysts said Q4FY26 figures were above estimates with generic drug substance inline as contract development and manufacturing (CDMO) performed brilliantly. EBITDA margin came in at 40% due to improved product mix as well as operating leverage.Analysts expect topline growth to remain strong at 20%+ CAGR during FY26-FY28. As discussed by management, they have raised FY27-FY29 earnings per share (EPS) estimates by 8% taking into account the Q4 beat, updated pipeline progress and revised business outlook.(Disclaimer: The recommendations and views given by experts on the stock market, other asset classes or personal finance management are their own. These opinions do not represent the views of The Times of India)
